


GENENT.093A



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Vanessa Hsei et al.

) Group Art Unit 1644

Appl. No. : 09/234,182

)

Filed : January 20, 1999

) I hereby certify that this correspondence and all
marked attachments are being deposited with the
United States Postal Service as first-class mail in
an envelope addressed to: United States Patent
and Trademark Office, P.O. Box 2327,
Arlington, VA 22202, on

For : ANTIBODY FRAGMENT
POLYMER CONJUGATES
AND HUMANIZED ANTI-IL-8
MONOClonal ANTIBODIES

) February 22, 2002
(Date)

Examiner : Dibrino, M.

) _____
Ginger R. Dreger Reg. No. 33,655

AMENDMENT AND RESPONSE TO OFFICE ACTION

Commissioner for Patents
United States Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

The present response is filed concurrently with filing of a Request for Continued Examination of the above-identified patent application. Please enter the following amendments, and consider the following arguments.

In the Claims:

Please amend claim 1 to read as follows:

1. (Twice amended) A conjugate of a single antibody fragment covalently attached to a single polyethylene glycol (PEG) molecule, wherein the antibody fragment is a Fab' comprising (1) a first chain that is either a light chain or a heavy chain and (2) a first opposite chain that is either a heavy chain opposite the first light chain or a light chain opposite the first heavy chain, wherein the PEG molecule is covalently attached to a first cysteine residue in the first chain that would ordinarily form a disulfide bridge with a second cysteine residue in the first opposite chain, wherein the disulfide bridge is avoided by substitution of another amino acid

TECH CENTER 1600
REC'D MAR 11 2002
1600
RECEIVED